WGS
GeneDx Holdings Corp.
NASDAQ · Healthcare · Medical - Healthcare Information Services · US
$101.10
−3.67%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$104.59
From 52W high−39.65%
Volume675530.00
Market cap$3.02B
P/E (TTM)—
P/S (TTM)6.6x
Div yield—
Key dataSep 18, 2026
Open
$104.59
From 52W high
−39.65%
Volume
675530.00
Market cap
$3.02B
ValuationView details →
P/E (Fwd)
154.3x
EV/EBITDA
−39.9x
P/E (TTM)
—
RSI (14)
68.3
MomentumView details →
1D Return
−3.67%
YTD Return
−23.19%
SummaryUpdated Jun 1, 2026
GeneDx Holdings Corp. (NASDAQ:WGS) is a patient-centered health intelligence company founded by Eric Schadt in October 2015 and headquartered in Stamford, Connecticut. The company went public in November 2020 and has established itself as a leader in genetic testing, particularly in pediatric and rare disease genomics. GeneDx operates the Centrellis health intelligence platform, which applies artificial intelligence and machine learning to clinical and genomic data to build comprehensive models of human health and provide personalized medical insights.
Similar companies
Latest newsMore news →
GeneDx and Beren Therapeutics launched NPC GenomeComplete, a new diagnostic product to improve diagnosis of Niemann-Pick disease type C.11d agoGeneDx Holdings Corp (WGS) shares rose 5.1% to $81.83 on August 11, 2026, in a volatile market.40d agoGeneDx launched a new online offering to improve accessibility of exome testing for children with global developmental delay, intellectual disability, and epilepsy.40d ago